Results 241 to 250 of about 3,189,219 (271)
Some of the next articles are maybe not open access.
Objectives and Mechanism of Iron Chelation Therapy
Annals of the New York Academy of Sciences, 2005Abstract: Prevention of cardiac mortality is the most important beneficial effect of iron chelation therapy. Unfortunately, compliance with the rigorous requirements of daily subcutaneous deferoxamine (DFO) infusions is still a serious limiting factor in treatment success.
Chaim, Hershko +3 more
openaire +2 more sources
Overview of Iron Chelation Therapy with Desferrioxamine and Deferiprone
Hemoglobin, 2009Chronic iron overload from frequent blood transfusions to treat patients with severe anemias leads to significant morbidity and mortality. Although desferrioxamine, the current standard of care, is an effective iron chelator with long-term evidence, it requires tedious subcutaneous infusion that reflects negatively on patient compliance.
M.D. Cappellini +2 more
openaire +2 more sources
The challenges of adherence and persistence with iron chelation therapy
International Journal of Hematology, 2011Due to advances in medical sciences, many chronic diseases that formerly resulted in early death can now be effectively managed with long-term treatment regimens. Patients with potentially fatal anemias, for example, can be treated with ongoing blood transfusions and iron chelation therapy.
Porter, John +2 more
openaire +3 more sources
Current hematology reports, 2006
Although iron chelation therapy with deferoxamine (DFO) has changed life expectancy in thalassemic patients, compliance with the rigorous requirements of long-term subcutaneous DFO infusions is unsatisfactory. This problem underlines the current efforts for developing alternative, orally effective chelators to improve compliance and treatment results ...
Chaim M, Hershko +3 more
openaire +1 more source
Although iron chelation therapy with deferoxamine (DFO) has changed life expectancy in thalassemic patients, compliance with the rigorous requirements of long-term subcutaneous DFO infusions is unsatisfactory. This problem underlines the current efforts for developing alternative, orally effective chelators to improve compliance and treatment results ...
Chaim M, Hershko +3 more
openaire +1 more source
New Advances in Iron Chelation Therapy
Hematology, 2006AbstractThe emergence of new chelators is likely to have a major impact on the treatment of thalassemia major, sickle cell disease and other hematologic disorders for which regular red cell transfusions are required either to correct severe anemia or to prevent major complications of the underlying disease.
openaire +2 more sources
Iron Chelation Therapy as a Modality of Management
Hematology/Oncology Clinics of North America, 2018Introduction of MRI techniques for identifying and monitoring tissue iron overload and the current understanding of iron homeostasis in transfusion-dependent (TDT) and non-transfusion-dependent thalassemia have allowed for a more robust administration of iron chelation therapies.
openaire +2 more sources
The aim of iron chelation therapy in thalassaemia
European Journal of Haematology, 2017The paper of Porter et al on the limitations of serum ferritin (SF) to predict liver iron concentration (LIC) highlights some important points for thalassaemia patients. However, some of the methods used and the relevant conclusions are misleading (1). This article is protected by copyright. All rights reserved.
openaire +2 more sources
THE MANAGEMENT OF IRON CHELATION THERAPY
British Journal of Haematology, 1983M J, Pippard, S T, Callender
openaire +2 more sources
Optic neuropathy in iron overload and iron chelation therapy
American Journal of Hematology, 2022Samyuktha Melachuri +2 more
openaire +2 more sources